AzTrials
AzTrials

HIV InfectionsSUSTAINNCT05040841

Supporting Sustained HIV Treatment Adherence After Initiation

A study testing M1/OTR: Immediate outreach to subject due to unsuppressed viral load test result, M2/PRM: Immediate outreach to subject after a missed pharmacy refill and M3/EAM: Immediate outreach to subject after EAM-identified missed doses in people with HIV Infections and Adherence, Medication, run by Boston University at 3 sites in South Africa.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The investigators will implement a 24-month fractional factorial design study (Aim 1). The investigators will recruit 510 patients initiating antiretroviral therapy (ART) at three City of Cape Town ART clinics. Each patient will have adherence monitored using the Wisepill® electronic adherence monitoring device (EAM). Read more about this study

Who is it for?
Ages 16 years and older
Conditions the study is for
HIV Infections, Adherence, Medication
What is being tested?
M1/OTR: Immediate outreach to subject due to unsuppressed viral load test result, M2/PRM: Immediate outreach to subject after a missed pharmacy refill and M3/EAM: Immediate outreach to subject after EAM-identified missed doses
Could I receive a placebo?
No, everyone receives an active treatment
How many people
534 participants
Where
3 sitesSouth Africa
Study dates
9 Mar 2022to 30 Jun 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 16 years and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Adults (≥18 years) and adolescents 16-17 years.
  • HIV-positive and attending a local City of Cape Town (COCT) clinic to commence ART.
  • Able to provide full informed consent, with a written signature. For those who are illiterate, a witness will be present throughout the process and will sign the form, while the participant will add their right thumb print. For those who are aged 16-17 years, informed written assent will be obtained, and the adolescent must have a parent or guardian who can provide full informed consent (see **below for how parent/guardian is defined for this purpose).
  • Access to a working cellphone and willingness to receive study-related messaging on that phone.
  • Willingness to comply with study procedures, including providing regular updates of contact details /locator information, and use a EAM device for the duration of participation.
  • Other Inclusion Criteria:
Show all 15Show fewer
  • Aim 1: In-depth interviews (IDIs) with subset of trial subjects at baseline and months 12 and 24.
  • Participation in the main trial.
  • Self-reported prior experience with substance use, depression, gender inequity, stigma, or transport/clinic issues.
  • Aim 2: Questionnaires and IDIs with staff members at study clinics (three total clinics).
  • Adults (≥18 years)
  • Staff at study clinics, providing HIV care and/or treatment.
  • Aim 2: Focus group discussion (FGD) with City of Cape Town officials.
  • Adults (≥18 years)
  • Staff at City of Cape Town.

Who cannot join

  • Clinical conditions as assessed by the COCT clinic clinicians at first visit e.g. renal disease, which preclude the use of a single tablet regimen (with the exception of those on tuberculosis (TB) treatment who are required to take an extra dose of dolutegravir daily).
  • Planning to leave Cape Town permanently within the next 24 months.
  • Being perinatally infected with HIV. Being infected from birth typically means a set of experiences and complications at a young age that require unique and special attention.
  • If an adolescent, taking their ART medication as a syrup, as they are required to use the electronic adherence monitor (Wisepill device), which is only suitable for tablets.
  • Other Inclusion Criteria:
  • Aim 1: IDIs with trial subjects.
Show all 10Show fewer
  • None.
  • Aim 2: Questionnaires and IDIs with staff members at clinics. • None.
  • Aim 2: FGD with City of Cape Town officials.
  • None.

Trial locations and contacts

3 sites in 1 country.

South Africa3 sites
  • Mzamomhle

    Cape Town, Western Cape

  • Phumlani

    Cape Town, Western Cape

  • Weltevreden Valley

    Cape Town, Western Cape

Other trials in South Africa

About this study

The investigators will implement a 24-month fractional factorial design study (Aim 1). The investigators will recruit 510 patients initiating antiretroviral therapy (ART) at three City of Cape Town ART clinics. Each patient will have adherence monitored using the Wisepill® electronic adherence monitoring device (EAM). After eligibility has been confirmed, each participant will be randomized to one of 16 experimental conditions. Each condition includes a unique combination of five adherence intervention components. Three of these components focus on identifying individuals with poor adherence, with increasing degrees of sophistication, with immediate linkage to adherence support. Two components focus on supporting good adherence. They both supplement the existing adherence support program delivered at the study clinics operated by City of Cape Town (standard of care component). Based on Self-Determination Theory, the investigators postulate these intervention components will: 1) enhance feelings of autonomy support, social support, and knowledge; 2) improve motivation and self-competence; and 3) increase ART retention, adherence, and viral suppression. A subset of the participants, as well as clinic staff, will be invited to in-depth interviews to explore mediating factors (Aim 1) and the implementation process (Aim 2); and the data collected in Aims 1 and 2 will be used to explore cost effectiveness (Aim 3).

Read the detailed description

The study's primary research goal is to identify the optimal combination of evidence-based and scalable HIV interventions for low-resource, high-burden settings. The investigators propose to 1) test the relative contribution of five promising intervention components; 2) collect cost and other implementation data; and 3) create a multi-component intervention package to optimize cost-effectiveness and implementation success. Of the five components, three are methods of non-adherence detection plus patient outreach; two are adherence support methods that can be integrated into Cape Town healthcare systems. These will not overcome all challenges that ART patients experience (e.g., structural barriers such as food insecurity) but they represent scalable, feasible, acceptable, and effective options. Notably, they are all behavioral approaches grounded in the experience and priorities of local health officials with whom the investigators have worked to identify scaleable interventions. While the study will be in Cape Town, it is broadly adaptable to other resource-limited settings.

The gold standard for testing interventions is the randomized controlled trial (RCT), which minimizes bias when testing cause and effect of a new exposure. When testing an intervention with more than one element, however, untangling the effect of individual elements is impossible. Indeed, data on the performance of individual components and their interactions-critical for developing and refining the components of a packaged intervention-is lost in an RCT. Notably, clinical care typically relies on packages of services, not single interventions, and packaged interventions are recommended for ART support. An effective way to test a multi-component intervention is to use the novel Multiphase Optimization STrategy (MOST), an engineering-inspired method for identifying the most efficacious combination of components in a packaged intervention, thus allowing researchers to drop inactive or weakly-performing components and construct an optimized package based on effect, cost, and other features. Once the optimized multi-component intervention is chosen, an RCT or quasi-experiment can follow to determine whether the optimized package yields superior outcomes compared to existing standards. MOST encompasses three phases: 1) preparation; 2) optimization; and 3) evaluation, often in an RCT. In this project, we have completed preparation, including a pilot study in Cape Town. SUSTAIN will comprise the middle optimization phase. The evaluation phase will be the focus of a future study.

The specific aims are:

Aim 1. Employ a highly efficient fractional factorial design to determine the effects of five intervention components on the primary outcome (HIV viral suppression) and secondary outcomes (ART adherence measured by EAM, ART retention per clinic records, days of unsuppressed virus, time to nonadherence detection, and time to linkage to support). The investigators will explore effect mechanisms quantitatively and qualitatively.

Aim 2. Evaluate the intervention components to address implementation, service, and client outcomes according to the Proctor framework. Data collection will involve tracking of intervention component use, time and motion studies, and quantitative surveys and qualitative interviews with participants and staff.

Aim 3. Use the effectiveness data collected in Aim 1 and the implementation and client outcomes in Aim 2 to model the multi-component intervention optimized for cost-effectiveness and implementation success.

Study Summary This study is designed to advance the translation of evidence-based interventions into clinical settings to benefit patients. There is ample evidence on what works to support ART adherence and retention-much of it from our own research. The investigators partnered with local officials and clinical staff in Cape Town to review the evidence and to conduct formative research to identify the most effective, acceptable, and feasible intervention options for patients and providers. The proposed study represents the next critical step: the investigators will test the intervention components that emerged from the formative work, encompassing elements to both rapidly identify nonadherent patients and to strengthen the support they receive once identified, to provide the data needed to construct the most cost-effective and sustainable multi-component intervention. The choice of intervention components will allow a critical test of advanced monitoring technology compared to simpler tools to identify nonadherence. By using an innovative MOST design to guide collection and analysis of efficacy, cost, and other implementation data, the study aligns with NIH's goals of using novel scientific methods to advance implementation science.

Being tested
M1/OTR: Immediate outreach to subject due to unsuppressed viral load test result, M2/PRM: Immediate outreach to subject after a missed pharmacy refill, M3/EAM: Immediate outreach to subject after EAM-identified missed doses, S1/Text: Weekly check-in texts, S2/Peer: Enhanced peer group support
Keywords
HIV treatment, HIV treatment adherence, Retention in care, Randomized controlled trial, Fractional factorial design, Proctor implementation science framework, Cost-effectiveness, South Africa, Community clinics
Medical subject headings
HIV Infections, Medication Adherence

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • M1/OTR: Immediate outreach to subject due to unsuppressed viral load test resultBehavioural

    Also called M1/OTR

    Standard of care viral loads are drawn at month 4, month 12 and annually thereafter. Those with a raised viral load are often not immediately recalled, but identified at their next visit (1-2 months later) and asked to attend the "Risk of Treatment Failure" (ROTF) clinic for adherence support when they next attend. For subjects assigned to M1 we will add a call or other outreach (e.g., text, Whatsapp, in accordance with the outreach methods subjects indicate are appropriate for them at the Enrollment visit); to the subject as soon as a raised viral load result is received (±3-5 days), thus expediting entry to existing adherence support. There are two chances to be identified as nonadherent and linked immediately to existing adherence support in the first 12 months of care with M1.

  • M2/PRM: Immediate outreach to subject after a missed pharmacy refillBehavioural

    Also called M2/PRM

    The subject will be contacted if he/she fails to collect medication from the pharmacy. A subject who is ≥7 days late for a monthly medication pick-up or 14 days late for a 2-monthly pick-up will be notified, again expediting entry to existing adherence support. There are 8-10 chances of being identified as nonadherent and linked immediately to existing adherence support in the first 12 months of care with M2.

  • M3/EAM: Immediate outreach to subject after EAM-identified missed dosesBehavioural

    Also called M3/EAM

    The subject will be contacted if he/she misses ≥4 doses or any three consecutive doses in a 14-day period, reviewed weekly, as identified by the EAM (electronic adherence monitor). There are 52 chances of being identified as nonadherent and linked immediately to existing adherence support in the first 12 months of care with M2.

  • S1/Text: Weekly check-in textsBehavioural

    Also called S1/Text

    Subject will receive weekly check-in texts in addition to the core adherence support component in the event they are identified as nonadherent and are linked with the Risk of Treatment Failure clinics. Subjects will be sent weekly simple but supportive text messages e.g. "how are you?" with the offer of a follow-up voice call for 16 consecutive weeks after being identified as nonadherent.

  • S2/Peer: Enhanced peer group supportBehavioural

    Also called S2/Peer

    Subject will receive an enhanced form of peer group support. Standard of care Basic peer groups are led by lay counsellors and provide social support and education; this will continue to be provided to all patients who are not assigned to the enhanced version. "Enhanced" peer group support will replace the Basic standard of care 4 x 60 minute peer groups; and aim to improve long-term maintenance of adherence through motivational interviewing over 4-8 weeks.

Study groups in NCT05040841
Study groupRoleWhat they receive
Condition 1ExperimentalIncludes 1 intervention: S2/Peer: Enhanced peer group support.
Receives: Behavioral: S2/Peer: Enhanced peer group support
Condition 2ExperimentalIncludes 1 intervention: S1/Text: Weekly check-in text messages.
Receives: Behavioral: S1/Text: Weekly check-in texts
Condition 3ExperimentalIncludes 1 intervention: M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient.
Receives: Behavioral: M3/EAM: Immediate outreach to subject after EAM-identified missed doses
Condition 4ExperimentalIncludes 3 interventions: M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient; S1/Text: Weekly check-in text messages; S2/Peer: Enhanced peer group support.
Receives: Behavioral: M3/EAM: Immediate outreach to subject after EAM-identified missed doses; Behavioral: S1/Text: Weekly check-in texts; Behavioral: S2/Peer: Enhanced peer group support
Condition 5ExperimentalIncludes 1 intervention: M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient.
Receives: Behavioral: M2/PRM: Immediate outreach to subject after a missed pharmacy refill
Condition 6ExperimentalIncludes 3 interventions: M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient S1/Text: Weekly check-in text messages; S2/Peer: Enhanced peer group support.
Receives: Behavioral: M2/PRM: Immediate outreach to subject after a missed pharmacy refill; Behavioral: S1/Text: Weekly check-in texts; Behavioral: S2/Peer: Enhanced peer group support
Condition 7ExperimentalIncludes 3 interventions: M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient; S2/Peer: Enhanced peer group support.
Receives: Behavioral: M2/PRM: Immediate outreach to subject after a missed pharmacy refill; Behavioral: M3/EAM: Immediate outreach to subject after EAM-identified missed doses; Behavioral: S2/Peer: Enhanced peer group support
Condition 8ExperimentalIncludes 3 interventions: M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient; M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient; S1/Text: Weekly check-in text messages.
Receives: Behavioral: M2/PRM: Immediate outreach to subject after a missed pharmacy refill; Behavioral: M3/EAM: Immediate outreach to subject after EAM-identified missed doses; Behavioral: S1/Text: Weekly check-in texts
Condition 9ExperimentalIncludes 1 intervention: M1/OTR: Outreach (OTR) to patient due to unsuppressed VL test result.
Receives: Behavioral: M1/OTR: Immediate outreach to subject due to unsuppressed viral load test result
Condition 10ExperimentalIncludes 3 interventions: M1/OTR: Outreach to patient due to unsuppressed VL test result; S1/Text: Weekly check-in text messages; S2/Peer: Enhanced peer group support.
Receives: Behavioral: M1/OTR: Immediate outreach to subject due to unsuppressed viral load test result; Behavioral: S1/Text: Weekly check-in texts; Behavioral: S2/Peer: Enhanced peer group support
Condition 11ExperimentalIncludes 3 interventions: M1/OTR: Outreach to patient due to unsuppressed VL test result; M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient; S2/Peer: Enhanced peer group support.
Receives: Behavioral: M1/OTR: Immediate outreach to subject due to unsuppressed viral load test result; Behavioral: M3/EAM: Immediate outreach to subject after EAM-identified missed doses; Behavioral: S2/Peer: Enhanced peer group support
Condition 12ExperimentalIncludes 3 interventions: M1/OTR: Outreach to patient due to unsuppressed VL test result; M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient; S1/Text: Weekly check-in text messages.
Receives: Behavioral: M1/OTR: Immediate outreach to subject due to unsuppressed viral load test result; Behavioral: M3/EAM: Immediate outreach to subject after EAM-identified missed doses; Behavioral: S1/Text: Weekly check-in texts
Condition 13ExperimentalIncludes 3 interventions: M1/OTR: Outreach to patient due to unsuppressed VL test result; M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient; S2/Peer: Enhanced peer group support.
Receives: Behavioral: M1/OTR: Immediate outreach to subject due to unsuppressed viral load test result; Behavioral: M2/PRM: Immediate outreach to subject after a missed pharmacy refill; Behavioral: S2/Peer: Enhanced peer group support
Condition 14ExperimentalIncludes 3 interventions: M1/OTR: Outreach to patient due to unsuppressed VL test result; M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient; S1/Text: Weekly check-in text messages.
Receives: Behavioral: M1/OTR: Immediate outreach to subject due to unsuppressed viral load test result; Behavioral: M2/PRM: Immediate outreach to subject after a missed pharmacy refill; Behavioral: S1/Text: Weekly check-in texts
Condition 15ExperimentalIncludes 3 interventions: M1/OTR: Outreach to patient due to unsuppressed VL test result; M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient; M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient.
Receives: Behavioral: M1/OTR: Immediate outreach to subject due to unsuppressed viral load test result; Behavioral: M2/PRM: Immediate outreach to subject after a missed pharmacy refill; Behavioral: M3/EAM: Immediate outreach to subject after EAM-identified missed doses
Condition 16ExperimentalIncludes 5 interventions: M1/OTR: Outreach to patient due to unsuppressed VL test result; M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient; M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient; S1/Text: Weekly check-in text messages; S2/Peer: Enhanced peer group support.
Receives: Behavioral: M1/OTR: Immediate outreach to subject due to unsuppressed viral load test result; Behavioral: M2/PRM: Immediate outreach to subject after a missed pharmacy refill; Behavioral: M3/EAM: Immediate outreach to subject after EAM-identified missed doses; Behavioral: S1/Text: Weekly check-in texts; Behavioral: S2/Peer: Enhanced peer group support

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. HIV viral suppression at 24 months

    This outcome will measure the effect of the interventions on HIV viral suppression from enrollment to the end of study participation. HIV viral suppression will be defined as % plasma viral load (VL) <50 copies/mL (dichotomous).

    Measured: 24 months

Secondary outcomes (6)
  1. HIV viral suppression at 12 months

    This outcome will be an intermediary outcome measure performed half-way through study participation. HIV viral suppression will be defined as % plasma VL <50 copies/mL (dichotomous).

    Measured: 12 months

  2. Change in HIV viral load between baseline and 12 months

    This will measure the effect on HIV viral load of exposure to interventions during the first half of study participation. It will be measured as the change in HIV viral load, defined as the mean change in HIV plasma between month 0 and month 12 post-enrollment (continuous).

    Measured: baseline, 12 months

  3. Change in HIV viral load between baseline and 24 months

    This will measure the effect on HIV viral load of exposure to interventions over the entire course of study participation. It will be measured as the change in HIV viral load, defined as the mean change in HIV plasma between month 0 and month 24 post-enrollment (continuous).

    Measured: baseline, 24 months

  4. Days of unsuppressed virus between baseline and 24 months

    This measure will determine the days that subjects experience unsuppressed virus, measured between baseline and the end of the study at 24 months (continuous).

    Measured: baseline, 24 months

  5. Achievement of ≥ 90% adherence in month 24

    This measure indicates whether subject achieved adherence of 90% or more during the final month of study participation in month 24 (dichotomous).

    Measured: month 24

  6. Mean adherence from baseline through 24 months

    This measure indicates mean adherence over the entire length of the study from enrollment through 24 months (continuous).

    Measured: baseline through 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Sep 2021
  2. Study start9 Mar 2022
  3. Primary completion28 May 2026
  4. Study completion30 Jun 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Factorial
Model description
The investigators will randomize subjects to one of 16 conditions, using a fractional factorial design to determine the effects of five intervention components.
Masking
None (open label)
Enrolment
534 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05040841
Sponsor's protocol ID
H-41920
Other IDs
1R01MH125703-01A1
Acronym
SUSTAIN
Status last verified
Jul 2026
First submitted
1 Sep 2021
Last updated
6 Jul 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: We have not yet made a detailed plan, but tentatively, we will deposit de-identified IPD in a repository at Boston University (BU) School of Public Health and the Desmond Tutu Health Foundation that can be made available to other researchers once our planned analyses are complete.

Publications

  • Jennings L, West RL, Halim N, Kaiser JL, Gwadz M, MacLeod WB, Gifford AL, Haberer JE, Orrell C, Sabin LL. Protocol for an evaluation of adherence monitoring and support interventions among people initiating antiretroviral therapy in Cape Town, South Africa-a multiphase optimization strategy (MOST) approach using a fractional factorial design. Trials. 2023 May 5;24(1):310. doi: 10.1186/s13063-023-07322-z.

    PubMed 37147725

Questions about this trial

What is this clinical trial studying?

A study testing M1/OTR: Immediate outreach to subject due to unsuppressed viral load test result, M2/PRM: Immediate outreach to subject after a missed pharmacy refill and M3/EAM: Immediate outreach to subject after EAM-identified missed doses in people with HIV Infections and Adherence, Medication, run by Boston University at 3 sites in South Africa.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 15 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 6 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in South Africa. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

HIV viral suppression at 24 months (time frame: 24 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05040841, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jul 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in